Rocket Pharmaceuticals Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data from Phase 1 Trial of RP-A501 for the Treatment of Danon Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/5/2026

1. KRG
2. SPY
3. ALAR
4. PRYMY
5. SKA-B
6. PBA
7. CCH:LN
8. META
9. BAJAJHFL:I
10. CCHGY

Go back to Rocket Pharmaceuticals Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data from Phase 1 Trial of RP-A501 for the Treatment of Danon Disease

Rocket Pharmaceuticals (RCKT) Announces $175M Proposed Public Offering of Common Stock

December 9, 2020 7:51 AM EST

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that it has commenced an underwritten public offering of $175 million of shares of its common stock. Rocket also intends to grant the underwriters a... More